HLA-C and neoplasm: For this strategy, T cells are harvested from the patient and genetically engineered to express transgenic T cell receptor (TCR) that recognise tumour-associated antigen (TAA) peptides presented by MHC molecules (Figure 1B) or chimeric antigen receptor (CAR) that recognise TAA protein expressed on the surface of tumour cells (Figure 1C).